Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.
Activation of the terminal pathway of complement on a membrane results in the generation of the membrane-damaging terminal C5b-9(m) complement complex, whereas the non-lytic water-soluble SC5b-9 complex is formed when complement is activated in the fluid phase. Both forms of the terminal complement complex (TCC) can be immunohistochemically detected, but not distinguished, by antibodies recognizing neoantigens in the complexes. By means of monoclonal antibodies against C9 neoantigens and against the S-protein, it was demonstrated that deposits of the TCC in tissue sections may be either in the form of C5b-9(m) or SC5b-9. The consequences of this for the interpretation of the histochemical data and the terminology of the two complexes are discussed.
Institute of Immunology and Rheumatology, National Hospital, Oslo, Norway.
T E
TE
Mollnes
M
M
Harboe
D000328:Adult; D000818:Animals; D000941:Antigens / Q000032:analysis; D003186:Complement C9 / Q000032:analysis; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis*; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D008562:Membrane Glycoproteins / Q000032:analysis; D051379:Mice; D009626:Terminology as Topic; D019096:Vitronectin
D000941:Antigens; D003186:Complement C9; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins; D008562:Membrane Glycoproteins; D019096:Vitronectin